ArticleFrontiers in oncology2026
A novel lipid droplet-related prognostic signature reveals CIDEC as a key biomarker for pancreatic adenocarcinoma.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Reprogramming of lipid metabolism is acknowledged as a key characteristic of cancer. This research aimed to examine the potential of lipid droplet-associated genes (LDRGs) in forecasting patient outcomes and the effectiveness of immunotherapy in pancreatic adenocarcinoma (PAAD). Methods: A predictive signature was developed through LASSO Cox regression analysis. Survival predictions were assessed via Kaplan-Meier survival analysis, along with univariate and multivariate Cox regression analyses. Associations between LDRGs and tumor-immune infiltration, as well as immune checkpoints, were examined using Spearman's analysis. The pivotal gene CIDEC within the LDRGs was pinpointed, and a CIDEC-associated competing endogenous RNA (ceRNA) regulatory network was established employing comprehensive bioinformatics analysis. The pro-tumor phenotype of CIDEC was explored in PAAD cell lines through molecular experiments. Results: A signature model related to LDRGs for determining the prognosis of PAAD was constructed, based on which patients were classified into two risk groups. A nomogram accompanied by calibration curves was constructed, which proved a robust predictive value. Additional investigations revealed that these prognostic LDRGs are significantly associated with levels of immune infiltration and the expression of immune checkpoints. Through ceRNA network analysis, a regulatory axis involving LINC00365, hsa-miR-32-5p, hsa-miR-363-3p, and CIDEC was identified in PAAD. Experimental evidence indicates that elevated CIDEC expression markedly enhances proliferation, migration, and invasion capabilities in PAAD cell lines while simultaneously suppressing apoptosis. Conversely, reduced CIDEC levels produce the opposite effects. Conclusion: In conclusion, our novel prognostic signature model has promising applications in PAAD patients. Within this framework, CIDEC may serve as a valuable candidate biomarker and a potential target for therapeutic intervention, thereby providing a basis for future research. The LINC00365/hsa-miR-32-5p/hsa-miR-363-3p/CIDEC regulatory axis may be involved in the progression of PAAD.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.